Drug-eluting stent

World's First FDA IDE Coronary Patient Treated With a DEB

Retrieved on: 
Friday, July 10, 2020

This is the first DEB accepted by the FDA for its 'Breakthrough Program'.

Key Points: 
  • This is the first DEB accepted by the FDA for its 'Breakthrough Program'.
  • "This first patient was treated with the investigational device after suffering a DES ISR.
  • We are delighted to be able to offer our patients this promising new technology," commented Professor Pascal Vranckx, Hartcentrum Hasselt, Belgium.
  • "No coronary drug-eluting balloon has yet been approved in the US, where ISR currently represents 11% of all stent implantations.

Growing Prevalence of CVD to Propel Massive Growth in Vascular Stents Market From 2019 to 2027: TMR

Retrieved on: 
Thursday, July 2, 2020

As per Transparency Market Research, "Global Vascular Stents market will record a Compound Annual Growth Rate of about 5% from 2019 to 2027.

Key Points: 
  • As per Transparency Market Research, "Global Vascular Stents market will record a Compound Annual Growth Rate of about 5% from 2019 to 2027.
  • One of the most notable factors leading to a higher demand is increase in incidence of cardiovascular diseases - takes about 17.9 million lives each year."
  • Key Findings of Global Vascular Stents Market Study:
    Key Drivers of Growth in Global Vascular Stents Market:
    The global vascular stents market is set to grow owing to multiple growth factors.
  • Gain business intelligence on global Vascular Stents Market (Type: Coronary Artery Stents [Bare Metal Stents, Bioresorbable Stents, Covered Stents, and Drug Eluting Stents], Peripheral Vascular Stents [Fem-pop Artery Stents, Iliac Artery Stents, and Infrapop Artery Stents], and Neurovascular Stents; Delivery Method: Balloon Expandable Stents and Self-expanding Stents; Material: Cobalt-Chromium Stent, Platinum-Chromium Stent, Nitinol Stent, Stainless Steel Stent, and Bioresorbable Polymer Stent; End User: Hospitals, Cardiac Centers, and Ambulatory Surgical Centers) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027 - https://www.transparencymarketresearch.com/report-toc/8191

Growing Prevalence of CVD to Propel Massive Growth in Vascular Stents Market From 2019 to 2027: TMR

Retrieved on: 
Thursday, July 2, 2020

As per Transparency Market Research, "Global Vascular Stents market will record a Compound Annual Growth Rate of about 5% from 2019 to 2027.

Key Points: 
  • As per Transparency Market Research, "Global Vascular Stents market will record a Compound Annual Growth Rate of about 5% from 2019 to 2027.
  • One of the most notable factors leading to a higher demand is increase in incidence of cardiovascular diseases - takes about 17.9 million lives each year."
  • Key Findings of Global Vascular Stents Market Study:
    Key Drivers of Growth in Global Vascular Stents Market:
    The global vascular stents market is set to grow owing to multiple growth factors.
  • Gain business intelligence on global Vascular Stents Market (Type: Coronary Artery Stents [Bare Metal Stents, Bioresorbable Stents, Covered Stents, and Drug Eluting Stents], Peripheral Vascular Stents [Fem-pop Artery Stents, Iliac Artery Stents, and Infrapop Artery Stents], and Neurovascular Stents; Delivery Method: Balloon Expandable Stents and Self-expanding Stents; Material: Cobalt-Chromium Stent, Platinum-Chromium Stent, Nitinol Stent, Stainless Steel Stent, and Bioresorbable Polymer Stent; End User: Hospitals, Cardiac Centers, and Ambulatory Surgical Centers) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027 - https://www.transparencymarketresearch.com/report-toc/8191

MedAlliance Gains CE Mark Approval for Coronary SELUTION SLR™ Sirolimus Drug Eluting Balloon

Retrieved on: 
Tuesday, June 30, 2020

NYON, Switzerland, June 30, 2020 /PRNewswire/ -- MedAlliance has announced the award of its second CE Mark: SELUTION SLR 014 PTCA, a novel Sirolimus Drug Eluting Balloon (DEB), for the treatment of coronary arterial disease.

Key Points: 
  • NYON, Switzerland, June 30, 2020 /PRNewswire/ -- MedAlliance has announced the award of its second CE Mark: SELUTION SLR 014 PTCA, a novel Sirolimus Drug Eluting Balloon (DEB), for the treatment of coronary arterial disease.
  • Investigators concluded that the data in this study support the safety, efficacy and optimal performance of SELUTION SLR in coronary applications.
  • In February 2020 MedAlliance received CE Mark approval for SELUTION SLR for treatment of peripheral artery disease.
  • Specializes in ground-breaking technology and commercialization of advanced drug device combination products for treatment of coronary and peripheral artery disease.

MedAlliance Gains CE Mark Approval for Coronary SELUTION SLR™ Sirolimus Drug Eluting Balloon

Retrieved on: 
Tuesday, June 30, 2020

NYON, Switzerland, June 30, 2020 /PRNewswire/ -- MedAlliance has announced the award of its second CE Mark: SELUTION SLR 014 PTCA, a novel Sirolimus Drug Eluting Balloon (DEB), for the treatment of coronary arterial disease.

Key Points: 
  • NYON, Switzerland, June 30, 2020 /PRNewswire/ -- MedAlliance has announced the award of its second CE Mark: SELUTION SLR 014 PTCA, a novel Sirolimus Drug Eluting Balloon (DEB), for the treatment of coronary arterial disease.
  • Investigators concluded that the data in this study support the safety, efficacy and optimal performance of SELUTION SLR in coronary applications.
  • In February 2020 MedAlliance received CE Mark approval for SELUTION SLR for treatment of peripheral artery disease.
  • Specializes in ground-breaking technology and commercialization of advanced drug device combination products for treatment of coronary and peripheral artery disease.

Elixir Medical Announces Outstanding 12-Month Data for DynamX Coronary Bioadaptor System, Demonstrating No Target Vessel Revascularization, No Thrombosis and Positive Adaptive Remodeling of the Artery

Retrieved on: 
Thursday, June 25, 2020

Elixir Medical , a developer of innovative, drug-eluting cardiovascular devices, today announced outstanding 12-month data for the DynamX Coronary Bioadaptor System , the first coronary artery implant that adapts to vessel physiology.

Key Points: 
  • Elixir Medical , a developer of innovative, drug-eluting cardiovascular devices, today announced outstanding 12-month data for the DynamX Coronary Bioadaptor System , the first coronary artery implant that adapts to vessel physiology.
  • DynamX is the first metallic coronary artery implant to demonstrate positive adaptive remodeling of the vessel, enabling it to expand to accommodate disease progression.
  • Physicians and their patients deserve a technology that treats coronary artery disease without making this compromise, said Elixir Medical CEO Motasim Sirhan.
  • The DynamX Bioadaptor is a metal implant coated in a drug-eluting bioresorbable polymer that initially supports the coronary artery during healing with radial strength, similar to DES.

Global Stents Market Analysis and Forecasts - Market Forecast to Grow at a CAGR of 5.21% During 2020-2025

Retrieved on: 
Friday, June 12, 2020

The stents market is estimated to grow at a CAGR of 5.21% during the forecast period 2020-2025.

Key Points: 
  • The stents market is estimated to grow at a CAGR of 5.21% during the forecast period 2020-2025.
  • The global stents market is estimated to witness significant growth during the forecast year due to increased incidence of heart-related diseases and huge demand for various diagnosis and treatment methods.
  • The global stents market is analyzed to be dominated by the coronary stents with a share of 58% in 2020.
  • Analyzes the market size and giving the forecast for current and future Stents market during the forecast period 2020-2023.

Global Stents Market Analysis and Forecasts 2020-2025 - ResearchAndMarkets.com

Retrieved on: 
Monday, June 8, 2020

The stents market is estimated to grow at a CAGR of 5.21% during the forecast period 2020-2025.

Key Points: 
  • The stents market is estimated to grow at a CAGR of 5.21% during the forecast period 2020-2025.
  • The global stents market is estimated to witness significant growth during the forecast year due to increased incidence of heart-related diseases and huge demand for various diagnosis and treatment methods.
  • The global stents market is analyzed to be dominated by the coronary stents with a share of 58% in 2020.
  • Analyzes the market size and giving the forecast for current and future Stents market during the forecast period 2020-2023.

Drug Eluting Stent Market Size Worth Around US$ 4,050 Mn 2027: Acumen Research and Consulting

Retrieved on: 
Tuesday, June 2, 2020

LOS ANGELES, June 2, 2020 /PRNewswire/ -- The global drug eluting stent market size is expected to be worth of around US$ 4,050 Mn by 2027 with 7% of CAGR.

Key Points: 
  • LOS ANGELES, June 2, 2020 /PRNewswire/ -- The global drug eluting stent market size is expected to be worth of around US$ 4,050 Mn by 2027 with 7% of CAGR.
  • Increasing technological advancement and regulatory approval by major players is the major driver for the growth of the drug eluting stent market.
  • A stringent regulation for product approval is a major factor expected to restraint the growth of the drug eluting stent market.
  • Moreover, the minimally invasive DES putting system improves the expansion of the drug eluting stent market.

The Global Resorbable Vascular Scaffold Market is expected to grow from USD 281.13 Million in 2018 to USD 659.13 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 12.94%

Retrieved on: 
Thursday, May 14, 2020

On the basis of Application, the Global Resorbable Vascular Scaffold Market is studied across Coronary Artery Stents and Peripheral Artery Stents.

Key Points: 
  • On the basis of Application, the Global Resorbable Vascular Scaffold Market is studied across Coronary Artery Stents and Peripheral Artery Stents.
  • On the basis of End User, the Global Resorbable Vascular Scaffold Market is studied across Ambulatory Surgical Centers, Cardiac Centers, and Hospitals.
  • What are the factors that affect the growth in the Global Resorbable Vascular Scaffold Market over the forecast period?
  • Which are the best product areas to be invested in over the forecast period in the Global Resorbable Vascular Scaffold Market?